Verdant PhytoMed — Executive Summary
Verdant PhytoMed (Pty) Ltd is a purpose-built, pharmaceutical-grade medicinal cannabis cultivation and processing company headquartered in Stellenbosch, Western Cape, South Africa. The Company is positioned to capitalise on the rapidly expanding global demand for medicinal cannabis products, leveraging South Africa’s competitive advantages…
Section 1 · Business Plan
Executive Summary
Verdant PhytoMed (Pty) Ltd is a purpose-built, pharmaceutical-grade medicinal cannabis cultivation and processing company headquartered in Stellenbosch, Western Cape, South Africa. The Company is positioned to capitalise on the rapidly expanding global demand for medicinal cannabis products, leveraging South Africa’s competitive advantages…
(~USD 6.5 million) to build a medicinal cannabis cultivation, processing and export facility in Stellenbosch, targeting ZAR 340 million in Year-5 revenue, a ~28% IRR and a 44% EBITDA margin.
Verdant PhytoMed (Pty) Ltd is a purpose-built, pharmaceutical-grade medicinal cannabis cultivation and processing company headquartered in Stellenbosch, Western Cape, South Africa. The Company is positioned to capitalise on the rapidly expanding global demand for medicinal cannabis products, leveraging South Africa’s competitive advantages in climate, cost of production, and geographic proximity to key export markets across the European Union, United Kingdom, and Australasia.
1.1 Investment Thesis
The global medicinal cannabis market is projected to grow from approximately USD 12.6 billion in 2023 to over USD 40 billion by 2032, representing a compound annual growth rate (CAGR) of approximately 14%. South Africa, with its favourable Mediterranean climate in the Western Cape, emerging regulatory framework under the South African Health Products Regulatory Authority (SAHPRA), and cost-competitive labour force, is uniquely positioned to emerge as a Tier 1 global supplier of pharmaceutical-grade cannabis.
Verdant PhytoMed’s strategy is differentiated by three core pillars: (i) regulatory-first approach with SAHPRA Section 22C licensing and EU-GMP certification at inception; (ii) export-oriented revenue model targeting established pharmaceutical distribution channels in Europe and the United Kingdom; and (iii) a management team combining deep pharmaceutical expertise with proven agribusiness operational capability.
1.2 Investment Highlights
-
Investment ask of ZAR 120 million (~USD 6.5 million) to fund infrastructure, licensing, and initial operations
-
Projected Year 3 revenue of ZAR 180 million, scaling to ZAR 340 million by Year 5
-
Target EBITDA margins of 36–44% at full operational maturity
-
Internal Rate of Return (IRR) of approximately 28% over a 5-year horizon
-
Break-even achieved in Year 2 of operations
-
Multiple exit pathways including trade sale, strategic acquisition, and potential JSE or international listing
1.3 Use of Funds
| Category | Allocation (%) | Amount (ZAR M) |
|---|---|---|
| Infrastructure (Greenhouses, Security) | 55% | 66.0 |
| Processing Facility (GMP Compliant) | 25% | 30.0 |
| Licensing & Compliance | 10% | 12.0 |
| Working Capital | 10% | 12.0 |
| Total | 100% | 120.0 |
1.4 Key Financial Metrics Summary
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 |
|---|---|---|---|---|---|
| Revenue (ZAR M) | 25 | 95 | 180 | 260 | 340 |
| EBITDA (ZAR M) | (10) | 20 | 65 | 104 | 150 |
| EBITDA Margin (%) | (40%) | 21% | 36% | 40% | 44% |
| Production (kg) | 2,500 | 5,500 | 8,000 | 11,000 | 14,000 |
| Headcount | 35 | 65 | 95 | 130 | 160 |
This document contains proprietary and confidential information. Distribution without written consent is prohibited.